Trial Search Results

Labor and Delivery Implant Insertion: A Randomized Controlled Trial

A barrier to initiating progestin contraceptives in the early postpartum period is the concern of interference with breastfeeding, specifically lactogenesis. In this trial, the investigators aim to add to safety data on the effects of immediate insertion of the contraceptive implant on breastfeeding. The investigators seek to examine the time to lactogenesis with immediate post-delivery insertion in delivery room versus insertion of a contraceptive implant in the postpartum ward prior to medical discharge. For this study, 82 consenting women will be randomized to immediate implant insertion (0-2 hours following delivery) in the delivery room or insertion of the implant following delivery in postpartum room and prior to medical discharge (24-48 hours following delivery).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Etonogestrel-Immediate
  • Drug: Etonogestrel-Delayed


Phase 3


Inclusion Criteria:

   - Healthy pregnant women

   - Intend to breastfeed

   - Desire the contraceptive implant as their method of contraception

   - Agree to be randomized to delivery room vs. postpartum ward insertion

Exclusion Criteria:

   - Not English or Spanish speaking

   - Allergy or Contraindication to contraceptive implant.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kate A Shaw, MD, MS
Not Recruiting